GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Gross Margin %

Prostatype Genomics AB (OSTO:PROGEN) Gross Margin % : 0.00% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Prostatype Genomics AB's Gross Profit for the three months ended in Jun. 2023 was kr0.06 Mil. Prostatype Genomics AB's Revenue for the three months ended in Jun. 2023 was kr0.06 Mil. Therefore, Prostatype Genomics AB's Gross Margin % for the quarter that ended in Jun. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Prostatype Genomics AB's Gross Margin % or its related term are showing as below:


During the past 5 years, the highest Gross Margin % of Prostatype Genomics AB was 25100.00%. The lowest was 274.93%. And the median was 3723.72%.

OSTO:PROGEN's Gross Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 46.64
* Ranked among companies with meaningful Gross Margin % only.

Prostatype Genomics AB had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Prostatype Genomics AB was 0.00% per year.


Prostatype Genomics AB Gross Margin % Historical Data

The historical data trend for Prostatype Genomics AB's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Gross Margin % Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
Gross Margin %
2,977.16 4,470.27 25,100.00 - 274.93

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prostatype Genomics AB's Gross Margin %

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Gross Margin % falls into.



Prostatype Genomics AB Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Prostatype Genomics AB's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=3.7 / 1.356
=(Revenue - Cost of Goods Sold) / Revenue
=(1.356 - -2.372) / 1.356
=274.93 %

Prostatype Genomics AB's Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=0.1 / 0.056
=(Revenue - Cost of Goods Sold) / Revenue
=(0.056 - 0) / 0.056
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Prostatype Genomics AB  (OSTO:PROGEN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Prostatype Genomics AB had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Prostatype Genomics AB Gross Margin % Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB (OSTO:PROGEN) Business Description

Traded in Other Exchanges
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines